Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12239716

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12239677

    Therapeutic bacteriophage compositions for treating Staphylococcus infection

    Armata Pharmaceuticals, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12239654

    Compounds and methods for treating neurological and cardiovascular conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12240902

    Anti-TREM2 antibodies and methods of use thereof

    DENALI THERAPEUTICS INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12241067

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12241068

    CD79-specific chimeric antigen receptor

    AUTOLUS LIMITED · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12240907

    N-terminal scFv multispecific binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12240816

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12239709

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12239694

    Methods and compositions for improved cognition

    The Regents of the University of California · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12239684

    Modulators of complement activity

    RA PHARMACEUTICALS, INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12239712

    Combination therapy for the treatment of liver disease

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Soricimed Biopharma Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12239638

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12240872

    Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

    Inovio Pharmaceuticals, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12239687

    Sustained release formulations using non-aqueous membrane emulsification

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12239656

    Nucleoporins as drug targets for anti-proliferative therapeutics

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12240917

    Anti-complement C1s antibodies and uses thereof

    Bioverativ USA Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. WO 2025046414

    VECTEURS DE CDV VIA ET LEURS UTILISATIONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Mar 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. WO 2025046413

    VECTEURS DE VIA DE VMN ET LEURS UTILISATIONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Mar 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. WO 2025047847

    VARIANT DE RÉGION Fc

    ASTELLAS PHARMA INC [JP] · Granted Thu Mar 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. WO 2025049275

    INHIBITEURS DE LA PROTÉINE DE LIAISON À L'ÉMOPAMIL ET LEURS UTILISATIONS

    BIOGEN MA INC [US] · Granted Thu Mar 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12247052

    CpG amphiphiles and uses thereof

    Elicio Therapeutics, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12246092

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Oxford Drug Design Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12247025

    Processes for preparation of soluble guanylate cyclase stimulators

    Cyclerion Therapeutics, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12247201

    Materials and methods for treatment of autosomal dominant retinitis pigmentosa

    CRISPR THERAPEUTICS AG · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12247245

    Selectivity screening for antimicrobial compounds

    Northwestern University · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12247978

    Compositions and methods for detection and treatment of coronavirus infection

    Arizona Board of Regents on Behalf of Northern Arizona University · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12246086

    Applications and imaging of shear-thinning biomaterial

    The Regents of the University of California · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12246096

    Self-assembled microcapsules with stimuli-responsive organic ligands

    The Regents of the University of California · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12246027

    Compositions of bile acids and phenylbutyrate compounds

    Amylyx Pharmaceuticals, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12246057

    Transmembrane stem cell factor (tm-SCF) lipid nanocarriers and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12246056

    Compositions and methods for the production of cysteine

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12246047

    Adeno-associated virus purification methods

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12246023

    Use of reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12246012

    Method for treating nervous system injuries using boldine and derivatives thereof

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12246011

    Radiation mitigator and method of use thereof

    The Board of Regents of the University of Oklahoma · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12247213

    Treatment of mucopolysaccharidosis IVA

    REGENXBIO INC. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12247059

    Conjugates of an IL-2 moiety and a polymer

    Nektar Therapeutics · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12247063

    Cell surface modification by coating with peptide amphiphiles (PAs)

    Northwestern University · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12247021

    Substituted tetrahydrofurans as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12247973

    Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

    UNIVERSITÄTSKLINIKUM REGENSBURG · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12246014

    Azetidine derivatives

    Ligand UK Development Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.